Cookies on the
LGC website
We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we’ll assume that you are happy to receive all cookies on the LGC website. However, if you would like to, you can change your cookie settings at anytime.
Question markFind out more

Neurodegeneration is an incurable, debilitating process which presents a growing global challenge due to our ageing population.

The European-funded project NeuroMET aims to develop a clinical and metrological framework to address the major patient needs, including earlier and more accurate diagnosis, more effective treatment and improved disease progression monitoring. This will be achieved though the development of diagnostic protocols, reference methods and the validation of patient centre outcome measures.

NeuroMET will work closely with clinical laboratories, hospitals and biopharmaceutical companies to ensure the effective exploitation of this project for the benefit of patients.

The background

Alzheimer’s disease and Parkinson’s disease are two of the most common neurodegenerative diseases that both involve the build-up of specific proteins in the brain and the destruction of brain cells. This leads to physical and mental impairment such as dementia, a condition that affects over 46 million people globally and costs around $800 billion per year in social and medical care. This represents a significant and growing problem for health care systems.

Early diagnosis of Alzheimer’s and Parkinson’s are essential for the success of their treatment and potential cure. However, there are currently no minimally invasive diagnostic tools which enable early diagnosis or effective monitoring of the progression of the disease within patients.

NeuroMET will address this challenge.


The project

For further detail on this project download the publishable summary.

The consortium

The consortium delivering NeuroMET brings together 9 partners from 5 countries across the EC with support from Parkinsons UK and the International Federation of Clinical Chemistry (IFCC).

It consists of:
 
  • five National Measurements Institutes/Designated Institutes (LGC, INRIM, LNE, PTB, SP)
  • two universities (UCL, UEA)
  • two hospitals (Charité, Centre Hospitalier Universitaire Montpellier)
 
EMPIR_neuromet-consortium-(1).png

 



Find out more

For a more detailed project overview, download the publishable summary

Highlights

Find out more about the first mini-syposium in Gothenburg

Upcoming events

Conference details

Recent publications

Publication details



Contact us

To find out more about this project email us.

Consortium members

Log-in to the NeuroMET Sharepoint site.